Stay updated on Alvocidib Biomarker AML Phase 2 Clinical Trial

Sign up to get notified when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Alvocidib Biomarker AML Phase 2 Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    No meaningful additions or deletions were detected between the screenshots; the page continues to present the study overview, eligibility criteria, and locations as before.
    Difference
    0.3%
    Check dated 2025-11-03T00:53:15.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    31 days ago
    Change Detected
    Summary
    Key updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.
    Difference
    3%
    Check dated 2025-10-05T08:04:49.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.
    Difference
    0.1%
    Check dated 2025-09-28T02:57:55.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Version label updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed, with no other substantive changes to core content.
    Difference
    0.2%
    Check dated 2025-09-13T17:16:02.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.2%
    Check dated 2025-09-06T14:47:33.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility names and locations, as well as a range of new chemical compounds and diseases, while removing several previous terms related to diseases and pharmacological agents.
    Difference
    6%
    Check dated 2025-08-30T11:32:30.000Z thumbnail image

Stay in the know with updates to Alvocidib Biomarker AML Phase 2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.